---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135260"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:57:10.805546+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q1 net loss $43.5M ($0.38/sh); launches PEMGARDA, guides 2024 rev $150-200M

## Summary
- Launched PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised; received CMS HCPCS Q and M codes.
- Cash $189.4M at Q1 end; expects ≥$75M year-end cash on $150-200M net product revenue.
- Net loss $43.5M vs $35.3M YoY; R&D $31.2M, SG&A $14.9M.
- Plans to submit EUA for pemivibart as COVID-19 treatment in immunocompromised via rapid immunobridging.
- Advancing VYD2311 mAb candidate optimized against BA.2.86/JN.1 lineages.

## SEC filing metadata
- accession: 0001193125-24-135260
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/0001193125-24-135260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/d838072d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135260
- JSON: https://secwatch.observer/filing/0001193125-24-135260.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135260.txt

## Key facts
- Earnings Releases
  Invivyd, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in, EPS Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in
  - EPS: Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 9, 2024, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024, and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/0001193125-24-135260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.